Peptide / Metabolic

Retatrutide

Triple agonist (GLP-1+GIP+glucagon). Investigational — NOT approved. Phase 3 trials ongoing. Most potent weight loss peptide trialled (~24% body weight reduction in Phase 2).

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose2 mg/week titrating to 12 mg/week (Phase 2 protocol)

Half-life144 hours

Risk flagmoderate

Regulatory noteResearch-only flag

Side effects and watch-outs

Nausea/vomiting (common)
Diarrhoea
Fatigue
Injection site reaction
Tachycardia (glucagon-mediated)
Pancreatitis risk
⚠️ Higher muscle wasting risk than mono/dual agonists
No approved formulation — compounded products are not standardized